<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436068</url>
  </required_header>
  <id_info>
    <org_study_id>832913</org_study_id>
    <nct_id>NCT04436068</nct_id>
  </id_info>
  <brief_title>Hyperfine Portable MRI in Hydrocephalus and Other Conditions Prompting Outpatient Brain Imaging</brief_title>
  <official_title>Evaluation of Hyperfine Low Field Strength Portable Point-of-Care Magnetic Resonance Imaging System in Hydrocephalus and Other Conditions Prompting Outpatient Brain Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with known or suspected hydrocephalus will receive brain scans using the&#xD;
      Hyperfine, low field strength, portable, magnetic resonance imaging (MRI) system in addition&#xD;
      to their scheduled outpatient standard of care clinical computed tomography (CT) or MRI scan.&#xD;
      The purpose of this pilot study is to evaluate the feasibility and acceptability of using the&#xD;
      Hyperfine system in an outpatient setting and to compare its diagnostic performance to&#xD;
      standard clinical imaging.&#xD;
&#xD;
      Outpatients with other known or suspected neurological disorders or conditions prompting&#xD;
      routine clinical brain imaging with MRI or CT will also be enrolled and the diagnostic&#xD;
      performance of low field scans compared to that of the same day standard of care clinical&#xD;
      imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydrocephalus is a medical condition in which an abnormal buildup of cerebrospinal fluid&#xD;
      (CSF) causes the fluid-filled spaces of the brain, the ventricles, to become enlarged.&#xD;
      Enlarged ventricles and increased intracranial pressure can cause headaches, dizziness,&#xD;
      blurred vision, cognitive impairment, gait disturbances and in severe cases even brain&#xD;
      herniation or death. A tube or shunt can be inserted into the ventricles to drain the CSF&#xD;
      either outside the body temporarily or into the abdominal cavity for long-term treatment.&#xD;
      Sometimes such shunts need to be adjusted or replaced if fluid re-accumulates. Medical&#xD;
      imaging scans, either computer tomography (CT) or magnetic resonance imaging (MRI), are used&#xD;
      to diagnose hydrocephalus in adults and children.&#xD;
&#xD;
      The purpose of this pilot study is to assess the performance of a newly developed, portable,&#xD;
      low-cost MRI machine (Hyperfine MRI) in diagnosing and following patients with hydrocephalus&#xD;
      in comparison to routine clinical CT or MRI. Outpatients with known or suspected&#xD;
      hydrocephalus with or without ventricular shunts will be recruited to undergo Hyperfine MRI&#xD;
      in conjunction with their routine clinical imaging. We will evaluate both the feasibility and&#xD;
      acceptability of using the Hyperfine unit in the outpatient setting as well as the&#xD;
      performance of Hyperfine MRI images in identifying hydrocephalus and other key brain imaging&#xD;
      features relative to routine CT and MRI.&#xD;
&#xD;
      Outpatients with other known or suspected neurological disorders or conditions prompting&#xD;
      routine clinical brain imaging with MRI or CT will also be enrolled and the diagnostic&#xD;
      performance of low field scans compared to that of the same day standard of care clinical&#xD;
      imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of hydrocephalus</measure>
    <time_frame>Through study completion, an average of 60 minutes</time_frame>
    <description>Presence or absence of hydrocephalus will be determined qualitatively based on neuroradiologist interpretation of low-field MRI scans and companion standard clinical MRI or CT scans to evaluate performance using the low-field device to make this determination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative ventricular volumes</measure>
    <time_frame>Through study completion, an average of 60 minutes</time_frame>
    <description>Quantitative ventricular volumes (mL) will be obtained and compared for low-field and companion standard clinical MRI scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of other important imaging findings</measure>
    <time_frame>Through study completion, an average of 60 minutes</time_frame>
    <description>Presence of other important imaging findings will be determined qualitatively based on neuroradiologist interpretation of low-field MRI scans and companion standard clinical MRI or CT scans.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hydrocephalus</condition>
  <condition>Neurological Disorder</condition>
  <arm_group>
    <arm_group_label>Outpatients with known or suspected hydrocephalus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatients with other known or suspected neurological condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperfine MRI scan</intervention_name>
    <description>Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.</description>
    <arm_group_label>Outpatients with known or suspected hydrocephalus</arm_group_label>
    <arm_group_label>Outpatients with other known or suspected neurological condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Suspected or confirmed diagnosis of hydrocephalus from Penn referring physician&#xD;
&#xD;
          -  Other suspected or confirmed neurological disorder from Penn referring physician&#xD;
&#xD;
          -  Routine clinical CT or MRI of the brain scheduled/obtained on the same day as&#xD;
             Hyperfine imaging.&#xD;
&#xD;
          -  Informed consent obtained from patient or legally authorized representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to routine 1.5T MRI evaluation, including electrical implants such&#xD;
             as cardiac pacemakers or perfusion pumps, ferromagnetic implants such as aneurysm&#xD;
             clips, surgical clips, protheses, artificial hearts or heart valves with steel parts,&#xD;
             metal fragments, shrapnel, tattoos near the eye, steel implants, or other irremovable&#xD;
             ferromagnetic objects&#xD;
&#xD;
          -  History of uncontrolled seizures&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Weight greater than or equal to 400lbs (181.4kg)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability or suspected inability to comply with the study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Karpf</last_name>
    <phone>215-662-7274</phone>
    <email>lauren.karpf@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Desiderio</last_name>
    <phone>610-721-3365</phone>
    <email>lisa.desiderio@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren N Karpf</last_name>
      <phone>215-662-7274</phone>
      <email>lauren.karpf@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Desiderio</last_name>
      <phone>610-721-3365</phone>
      <email>lisa.desiderio@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joel Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Joel M. Stein, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>CT</keyword>
  <keyword>Shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

